Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
100%
Hepatitis C Virus
62%
Hepatitis C
35%
Hematologic Malignancy
27%
Hepatitis B Virus
21%
Infection
18%
Antiviral Drug
18%
Chemotherapy
17%
Chronic Hepatitis C
15%
Observational Study
12%
Invasive Aspergillosis
12%
Amphotericin B
12%
Immune Checkpoint Inhibitor
11%
HIV
11%
Liver Cell Carcinoma
9%
Virus Infection
9%
Hepatitis B
8%
Solid Malignant Neoplasm
8%
Monotherapy
7%
Antiviral Therapy
6%
Diseases
6%
Ribavirin
6%
Caspofungin
5%
Triazole
5%
Case-Control Study
5%
Aspergillus fumigatus
5%
Leukemia
5%
Posaconazole
5%
Respiratory Syncytial Virus Infection
5%
Hepatitis E Virus
5%
Antivirus Agent
5%
Adverse Event
5%
Keyphrases
Hepatitis C Virus
37%
Cancer Patients
33%
Hepatitis C Virus Infection
24%
Patients with Cancer
21%
In Cancer
21%
Hematological Malignancies
19%
Chronic Hepatitis C Virus Infection
13%
Hepatitis C Virus Reactivation
12%
Infected Patients
12%
Invasive Aspergillosis
11%
Hepatitis B Virus
11%
B Hepatitis
10%
Liposomal Amphotericin B
10%
Hepatitis C Virus Screening
10%
Cancer Center
9%
Sustained Virological Response
9%
Prospective Observational Study
9%
Risk Factors
8%
Immune Checkpoint Inhibitors
8%
Tertiary Care
8%
Confidence Interval
7%
Direct-acting Antivirals
7%
Antiretroviral Therapy
6%
Hepatitis B Virus Reactivation
6%
Hepatocellular Carcinoma
6%
Lymphoma
6%
Cancer Treatment
6%
Anti-hepatitis C Virus
6%
Leukemia
5%
SVR12
5%
Cytomegalovirus Pneumonia
5%
Improved Outcomes
5%
Oncologic
5%
Respiratory Syncytial Virus Infection
5%
Tertiary Cancer Center
5%
Caspofungin
5%
Hepatitis E Virus Infection
5%
Ribavirin
5%
Monotherapy
5%
Adjusted Odds Ratio
5%
Medicine and Dentistry
Malignant Neoplasm
55%
Hepatitis C Virus
54%
Hepatitis C
28%
Hematologic Malignancy
19%
Infection
17%
Hepatitis B Virus
13%
Chronic Hepatitis C
12%
Virus Reactivation
10%
Antiviral Drug
10%
Cancer Therapy
10%
Cancer Treatment
9%
Hepatocellular Carcinoma
9%
Observational Study
8%
Case-Control Study
8%
Tertiary Care
8%
Cytomegalovirus
8%
Cancer
8%
Human immunodeficiency virus
7%
Odds Ratio
7%
Antiviral Therapy
7%
Hepatitis B
6%
Diseases
6%
Diffuse Large B-Cell Lymphoma
6%
Solid Malignant Neoplasm
5%
Patient with Leukemia
5%
HIV Test
5%
Cytomegalovirus Infection
5%
Prevalence
5%